M. Disis

Steven Piantadosi, Vered Stearns, Barbara Biedrzycki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent

M. Disis, E. Gad, Y. Dang, 2015, Clinical Cancer Research.

Antigen-Specific Cancer Vaccines

K. Knutson, K. Schiffman, M. Disis, 2003 .

The Prostate 47:222^229 (2001) Naturally Occurring Prostate Cancer Antigen- Specific T Cell Responses of aTh1Phenotype Can Be Detectedin Patients With Prostate Cancer

W. Ellis, P. Lange, C. Higano, 2022 .

Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells

L. Standish, Hailing Lu, M. Disis, 2010, Clinical Cancer Research.

Cancer Therapy : Preclinical Polysaccharide Krestin Is a Novel TLR 2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD 8 T Cells and NK Cells

L. Standish, Hailing Lu, M. Disis, 2010 .

Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice

E. Lee, Yeul-Hong Kim, J. Seo, 2014, Breast Cancer Research and Treatment.

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

irect detection of carcinoembryonic antigen autoantibodies in clinical human erum samples using a surface plasmon resonance sensor on Ladda

Shaoyi Jiang, Shaoyi Jiang, Hailing Lu, 2009 .

Protein-bound polysaccharide-K induces IL-1β via TLR2 and NLRP3 inflammasome activation

L. Standish, Hailing Lu, M. Disis, 2014, Innate immunity.

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

L. Chow, R. Hershberg, Hailing Lu, 2016, PloS one.

Dendritic Cell–Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Specific Induction of Immunosuppressive Cells

M. Disis, E. Gad, Y. Dang, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Dendritic Cell – Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Speci fi c Induction of Immunosuppressive Cells

M. Disis, E. Gad, Y. Dang, 2012 .

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

D. McNeel, K. Knutson, K. Schiffman, 2000, Breast Cancer Research and Treatment.

A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab.

J. Waisman, M. Disis, L. Salazar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients

K. Knutson, K. Schiffman, M. Disis, 2004, Journal of Clinical Immunology.

T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity

S. Plymate, M. Disis, D. Cecil, 2013, Breast Cancer Research and Treatment.

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

K. Kelly, G. Weiss, A. Heydebreck, 2016 .

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.

K. Kelly, G. Weiss, J. Infante, 2015 .

Toward a stem cell gene therapy for breast cancer.

S. Tuve, H. Kiem, N. Kiviat, 2009, Blood.

Towards a stem cell gene therapy for breast cancer

S. Tuve, H. Kiem, N. Kiviat, 2009 .

neu Antigen-Negative Variants Can Be Generated after neu-Specific Antibody Therapy in neu Transgenic Mice

K. Knutson, M. Disis, Y. Dang, 2004, Cancer Research.

Tumor Antigen–Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming

K. Knutson, M. Disis, L. Salazar, 2006, Clinical Cancer Research.

Distinct Phenotype and Cytokine Signature Antigens in Breast Cancer Patients Have a Functional T Cell Responses to Tumor

P. Haaland, V. Maino, M. Inokuma, 2007 .

Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy

M. Disis, 2008 .

' s response to reviews Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 Title : breast cancer cells

B. Wallden, M. Emond, P. Newmark, 2005 .

Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity.

B. Goff, M. Disis, S. Parker, 2016 .

TLR8 ligation induces apoptosis of monocytic myeloid‐derived suppressor cells

R. Hershberg, Hailing Lu, M. Disis, 2018, Journal of leukocyte biology.

Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy.

M. Disis, L. Salazar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy in breast cancer: An introduction.

M. Disis, S. Stanton, 2018, Breast.

Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients

S. Hanash, Hiroyuki Katayama, James E. Annis, 2021, npj Breast Cancer.

Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv–expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion

K. Knutson, I. Hellstrom, K. Hellstrom, 2006, Molecular Cancer Therapeutics.

Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial

K. Allison, J. Waisman, Hailing Lu, 2017, JAMA oncology.

Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy

M. Atkins, J. Kirkwood, V. Maino, 2002, Journal of immunotherapy.

Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting

P. Brown, R. Glynn, M. You, 2021, Journal of cancer prevention.

The Antigenic Repertoire of Premalignant and High-Risk Lesions

M. Disis, S. Stanton, J. Marquez, 2015, Cancer Prevention Research.

Identification of Putative Immunologic Targets for Colon Cancer Prevention Based on Conserved Gene Upregulation from Preinvasive to Malignant Lesions

D. Pritchard, James E. Annis, M. Disis, 2013, Cancer Prevention Research.

Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs.

Forrest M Kievit, Tingzhong Wang, Miqin Zhang, 2012, ACS nano.

Immunity to Oncogenic Proteins

Wei Chen, J. Gralow, M. Cheever, 1995, Immunological reviews.

Therapeutic cancer vaccines revamping: technology advancements and pitfalls

G. Curigliano, P. Romero, M. Disis, 2021, Annals of Oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

H. Rugo, S. Adams, A. Cimino-Mathews, 2021, Journal for ImmunoTherapy of Cancer.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.

K. Schiffman, M. Disis, V. Goodell, 2005, Cancer research.

Immunologic principles and immunotherapeutic approaches in ovarian cancer.

T. Curiel, K. Knutson, M. Disis, 2003, Hematology/oncology clinics of North America.

HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase

D. McNeel, L. Fong, T. Frye, 2010, Cancer Immunology, Immunotherapy.

Peptide-Based Vaccines

K. Knutson, M. Disis, L. Salazar, 2004 .

Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant.

Hailing Lu, M. Disis, A. Engel, 2013, Immunobiology.

TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy

L. Standish, Hailing Lu, M. Disis, 2011, Clinical Cancer Research.

Leveraging premalignant biology for immune-based cancer prevention

J. Mesirov, T. Ideker, T. Rebbeck, 2016, Proceedings of the National Academy of Sciences.

The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens.

Hailing Lu, K. Knutson, M. Disis, 2006, Cancer research.

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health

G. Colditz, B. Kramer, T. Rebbeck, 2018, Cancer Prevention Research.

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

S. Adams, M. Disis, Mary L Disis, 2016, JAMA oncology.

Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition1

Hailing Lu, K. Knutson, M. Disis, 2006, The Journal of Immunology.

TNM staging in colorectal cancer: T is for T cell and M is for memory.

M. Disis, E. Broussard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

M. Disis, 2011, Cancer Immunology, Immunotherapy.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Joseph F. Murphy, V. Thorsson, F. Marincola, 2019, Journal of Immunotherapy for Cancer.

Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK

Hailing Lu, M. Disis, E. Gad, 2013, Cancer Immunology, Immunotherapy.

Augments ADCC VTX-2337 Is a Novel TLR 8 Agonist That Activates NK Cells and Updated

J. Howbert, V. Maino, R. Hershberg, 2012 .

Cancer Therapy : Preclinical VTX-2337 Is a Novel TLR 8 Agonist That Activates NK Cells and Augments ADCC

J. Howbert, V. Maino, R. Hershberg, 2012 .

VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

J. Howbert, V. Maino, R. Hershberg, 2011, Clinical Cancer Research.

Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers

D. Albertson, Mamie Yu, A. Paradiso, 2006, Genes, chromosomes & cancer.

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention

R. Lubet, M. Disis, D. Cecil, 2021, Frontiers in Immunology.

Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.

B. Ksander, K. Knutson, M. Disis, 2006, Cancer research.

Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera

S. Hanash, R. Prentice, Ziding Feng, 2012, Cancer Prevention Research.

Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer.

Hailing Lu, M. Disis, V. Goodell, 2008, Journal of proteome research.

Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer

Hailing Lu, M. Disis, V. Goodell, 2007, Expert opinion on therapeutic targets.

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

K. Kelly, A. Heydebreck, J. Grewal, 2019, JAMA oncology.

Multimetric feature selection for analyzing multicategory outcomes of colorectal cancer: random forest and multinomial logistic regression models

Lanjing Zhang, M. Disis, Chao Cheng, 2021, Laboratory Investigation.

Chitosan-alginate 3d Scaffolds as a Mimic of the Glioma Tumor Microenvironment

Stephen J. Florczyk, Forrest M Kievit, Miqin Zhang, 2022 .

Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer

M. Gormley, A. Timms, M. Disis, 2022, Scientific Reports.

Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer

W. Watt, M. Disis, M. Disis, 2017, Seminars in Immunopathology.

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

James Y. Dai, A. Tinker, B. Goff, 2021, Journal for ImmunoTherapy of Cancer.

Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets.

Hailing Lu, M. Disis, S. Stanton, 2019, Vaccine.

A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop

S. Hilsenbeck, J. V. Von Roenn, L. Ellis, 2021, Clinical Cancer Research.

Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer

M. Disis, D. Cecil, Mary L Disis, 2015, Journal of Immunotherapy for Cancer.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

S. H. van der Burg, F. Marincola, A. Palucka, 2011, Clinical Cancer Research.

Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients

S. Hanash, Hiroyuki Katayama, James E. Annis, 2021, npj Breast Cancer.

An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis.

J. Manson, S. Hanash, R. Prentice, 2015, Cancer research.

Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models

P. Treuting, M. Disis, S. Stanton, 2014, Breast Cancer Research and Treatment.

Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer

S. Hanash, Hailing Lu, M. Disis, 2014, Journal of Translational Medicine.

Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.

M. Disis, K. Park, E. Gad, 2008, Cancer research.

Immunologic Approaches to Breast Cancer Therapy

M. Disis, S. Stanton, E. Ramos, 2018 .

Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity

J. Waisman, M. Disis, L. Salazar, 2008, Molecular Cancer Therapeutics.

A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease

P. Treuting, R. Lubet, M. Disis, 2013, Cancer Prevention Research.

Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

M. Disis, D. Cecil, K. Park, 2014, Cancer research.

Progress in the development of a therapeutic vaccine for breast cancer.

M. Disis, A. Coveler, N. Bates, 2010, Breast cancer.

Peptide-based tumor vaccines

D. McNeel, K. Knutson, K. Schiffman, 2008 .

Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells.

Stephen J. Florczyk, Forrest M Kievit, Miqin Zhang, 2013, Biomacromolecules.

Triple-negative breast cancer: immune modulation as the new treatment paradigm.

M. Disis, Mary L Disis, S. Stanton, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Cancer Immunol Immunother DOI 10.1007/s00262-006-0194-y REVIEW

K. Knutson, M. Disis, L. Salazar, 2006 .

Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.

M. Disis, M. O'Meara, 2011, Omics : a journal of integrative biology.

Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy TLR2 Agonist PSK Activates Human NK Cells and Enhances the

L. Standish, Hailing Lu, M. Disis, 2011 .

AWARD NUMBER: W81XWH-07-1-0525 TITLE: CD8 T Cells and Immunoediting of Breast Cancer PRINCIPAL INVESTIGATOR: Keith L. Knutson CONTRACTING ORGANIZATION: Mayo Clinic

K. Knutson, M. Disis, C. Erskine, 2009 .

Adoptive T-cell therapy for the treatment of solid tumours

D. Mankoff, K. Knutson, K. Schiffman, 2002, Expert opinion on biological therapy.

A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer.

J. Waisman, M. Disis, L. Salazar, 2014 .

Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Vaccine Given Concurrently with Trastuzumab in Patients with Newly Diagnosed Advanced Stage Breast Cancer.

J. Waisman, M. Disis, L. Salazar, 2009 .

Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine

E. Jaffee, S. Piantadosi, L. Emens, 2008 .

Circulating Immune Complexes in Cystic Fibrosis and Their Correlation to Clinical Parameters

R. Kobayashi, M. Disis, M. Disis, 1986, Pediatric Research.

ELISpot for measuring human immune responses to vaccines

M. Disis, Jong-Baeck Lim, Y. Dang, 2011, Expert review of vaccines.

Antibodies to human tumor oncoproteins in cancer patients

M. Disis, L. Salazar, 2003 .

proliferation and synergistic antitumor response E s provides intratumoral T E T + s) combined with CD8 E cells (T T effector + Adoptive transfer of tumor-primed, in vitroactivated, CD4

G. Plautz, M. Disis, S. Shu, 2008 .

Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.

G. Plautz, M. Disis, S. Shu, 2007, Blood.

Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.

B. Goff, Leonard D'Amico, M. Disis, 2017, Gynecologic oncology.

Immunologic targets for breast cancer1

M. Disis, 2002 .

CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer.

Forrest M Kievit, Miqin Zhang, Forrest M. Kievit, 2014, Anti-cancer agents in medicinal chemistry.

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

M. Cheever, K. Knutson, K. Schiffman, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals”

M. Manjili, K. Knutson, M. Disis, 2006, Breast Cancer Research and Treatment.

T‐Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR‐ABL a

D. Peace, M. Cheever, M. Disis, 1993, Annals of the New York Academy of Sciences.

Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer.

M. Disis, 2015, JAMA oncology.

A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102

Soldano Ferrone, James N Ingle, L. Hartmann, 2010, Clinical Cancer Research.

An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.

L. Hartmann, P. Wettstein, K. Knutson, 2008, Cancer research.

Therapeutic vaccines for ovarian cancer.

M. Disis, J. Liao, 2013, Gynecologic oncology.

Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity

M. Disis, L. Salazar, A. Coveler, 2008, Breast Cancer Research and Treatment.

The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity.

K. Knutson, M. Disis, C. Erskine, 2008, Blood.

enhanced antibody immunity The endogenous danger signal, crystalline uric acid, signals for

K. Knutson, M. Disis, C. Erskine, 2008 .

Phase II Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab

M. Disis, 2010 .

Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model

Jeong-An Gim, Yeul Hong Kim, M. Disis, 2022, Journal for ImmunoTherapy of Cancer.

Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer

S. Hanash, M. Disis, S. Stanton, 2013, Journal of Immunotherapy for Cancer.

General Approaches to Measuring Immune Responses

K. Knutson, M. Disis, 2007 .

Immunotherapy of glioblastoma multiforme

K. Knutson, K. Schiffman, M. Disis, 2003, Expert review of neurotherapeutics.

Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers

P. Senter, M. Disis, D. Cecil, 2020, Molecular Cancer Therapeutics.

Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses

M. Disis, D. Cecil, Y. Dang, 2021, Clinical Cancer Research.

In situ adenovirus vaccination engages T effector cells against cancer.

Y. Liu, S. Tuve, S. Roffler, 2009, Vaccine.

Immunotherapy for breast cancer.

M. Bishop, K. Knutson, K. Schiffman, 2017, Cancer chemotherapy and biological response modifiers.

Laboratory analysis of T-cell immunity.

K. Knutson, M. Disis, C. dela Rosa, 2006, Frontiers in bioscience : a journal and virtual library.

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen

L. Hartmann, A. Nassar, J. Ingle, 2009, Cancer Immunology, Immunotherapy.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer

A. Jazaeri, T. Curiel, A. Mills, 2023, Journal for ImmunoTherapy of Cancer.

Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine.

K. Guthrie, K. Knutson, M. Disis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer.

J. Waisman, M. Disis, L. Salazar, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I studies of drug combinations.

J. Verweij, S. Cannistra, M. Disis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer

S. Hanash, Hailing Lu, M. Disis, 2014, Journal of Translational Medicine.

Abstract 6593: PRGN-3005 UltraCAR-T™: multigenic CAR-T cells generated using non-viral gene delivery and rapid manufacturing process for the treatment of ovarian cancer

H. Sabzevari, T. Chan, M. Disis, 2020 .

COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of Type I tumor infiltrating lymphocytes.

R. Lubet, M. Disis, D. Cecil, 2022, Cancer prevention research.

P1-13-04: Phase II Study of Topical Imiquimod and Abraxane for Treatment of Breast Cancer Cutaneous Metastases.

H. Gray, Hailing Lu, M. Disis, 2011 .

Th1 epitope selection for clinically effective cancer vaccines

W. Watt, M. Disis, D. Cecil, 2014, Oncoimmunology.

Cancer vaccines targeting the HER2/neu oncogenic protein.

K. Schiffman, M. Disis, M. Disis, 2001, Seminars in oncology.

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

K. Knutson, M. Disis, M. Disis, 2005, Cancer Immunology, Immunotherapy.

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

J. Gralow, M. Cheever, M. Disis, 1996, Journal of immunology.

Tumor vaccines for the management of prostate cancer.

D. McNeel, M. Disis, M. Disis, 2000, Archivum immunologiae et therapiae experimentalis.

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

M. Cheever, M. Disis, M. Disis, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Oncogenic proteins as tumor antigens.

M. Cheever, M. Disis, M. Disis, 1996, Current opinion in immunology.

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

K. Knutson, K. Schiffman, M. Disis, 2001, The Journal of clinical investigation.

Vaccination against the HER-2/neu oncogenic protein.

K. Knutson, K. Schiffman, M. Disis, 2002, Endocrine-related cancer.

HER-2/neu oncogenic protein: issues in vaccine development.

M. Cheever, M. Disis, M. Disis, 1998, Critical reviews in immunology.

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

J. Gralow, M. Cheever, M. Disis, 1996, Blood.

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

Wei Chen, B. Groner, R. Livingston, 1994, Cancer research.

TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells

R. Hershberg, Hailing Lu, T. Spies, 2013, Journal of Immunotherapy for Cancer.

Progress in the development of a therapeutic vaccine for breast cancer

M. Disis, A. Coveler, N. Bates, 2010 .

Progress in the development of a therapeutic vaccine for breast cancer

M. Disis, A. Coveler, N. Bates, 2010 .

Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein.

Wei Chen, D. Peace, M. Cheever, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor.

Shaoyi Jiang, Hailing Lu, Allen D. Taylor, 2009, Colloids and surfaces. B, Biointerfaces.

Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report

R. Shoemaker, E. Jaffee, J. Schlom, 2022 .

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

M. Cheever, M. Disis, M. Disis, 1997, Advances in cancer research.

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

S. Ménard, J. Gralow, R. Dittadi, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Movie Review of The Immortal Life of Henrietta Lacks.

M. Disis, 2017, JAMA.

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.

D. McNeel, T. Gooley, K. Knutson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.